A Takeda spokesperson told Fierce Biotech that it was on track to open its new R&D facility being developed by BioMed Realty ...

Following Moderna's public rebuke of the FDA's refusal to take up its application for a next-gen flu vaccine, the regulator has doubled down and accused Moderna of potentially putting patients at risk ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra. | Madrigal Pharmaceuticals is continuing to ...

A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week regimen achieving a Tezspire-like reduction in the annualized asthma exacerbation ...

GE HealthCare has launched a new technology designed to help hospitals keep up with the maintenance and repair demands of a growing number of connected medical devices. | GE HealthCare has launched a ...

During the first year of the Trump administration, signs of an anti-mRNA slant within the FDA and the Department of Health ...

Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...

German Merck has set up a new collaboration with U.K. medtech company Calla Lily Clinical Care to work on its next-generation ...

Evommune has aced its first major test as a public company, reporting phase 2a eczema data that caused its share price to jump 75% in premarket trading. The biotech, which went public late last year, ...

In October of last year, Kailera Therapeutics unveiled a whopping $600 mill | Kailera Therapeutics and its China partner ...

ILiAD Biotechnologies has closed an oversubscribed $115 million series B fundraise to support the company’s next-generation ...